Matches in Wikidata for { <http://www.wikidata.org/entity/Q66060286> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q66060286 description "clinical trial" @default.
- Q66060286 description "ensayu clínicu" @default.
- Q66060286 description "klinisch onderzoek" @default.
- Q66060286 description "клінічне випробування" @default.
- Q66060286 description "կլինիկական փորձարկում" @default.
- Q66060286 name "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 name "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 type Item @default.
- Q66060286 label "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 label "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 prefLabel "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 prefLabel "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FL" @default.
- Q66060286 P1050 Q66060286-2659D1BD-0103-4A72-978C-3B83A1CD7D76 @default.
- Q66060286 P1050 Q66060286-7EC3FAFF-2853-4CA3-B528-6952114C396A @default.
- Q66060286 P1132 Q66060286-27BCE363-2F22-47B2-9823-952C70529B4A @default.
- Q66060286 P1476 Q66060286-9CB050D3-3F26-4758-B880-67854E07D87B @default.
- Q66060286 P1813 Q66060286-F214708A-310B-4969-A6D5-FD2B17B1DEB9 @default.
- Q66060286 P2899 Q66060286-2DECC720-6E19-4DCE-AF5E-C70ECED86EE6 @default.
- Q66060286 P3098 Q66060286-859F5EC7-37E8-4676-8DDF-F839D84B65C5 @default.
- Q66060286 P31 Q66060286-C0D055E4-8C72-40C2-807E-27D244CEBA62 @default.
- Q66060286 P580 Q66060286-93B1DF3F-8615-4DE1-A5AD-A3609D7126CF @default.
- Q66060286 P582 Q66060286-5B8703AD-1B3D-405D-A859-054969267C9E @default.
- Q66060286 P6099 Q66060286-C78AC259-FE4F-4F01-8CC0-7F6D73F06154 @default.
- Q66060286 P6153 Q66060286-A53C22E0-AAE1-4C1B-A409-B74765A21AAA @default.
- Q66060286 P8363 Q66060286-3AF5A5FE-D294-4B35-B040-7926C3A32A42 @default.
- Q66060286 P1050 Q179630 @default.
- Q66060286 P1050 Q29496 @default.
- Q66060286 P1132 "+768" @default.
- Q66060286 P1476 "A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)" @default.
- Q66060286 P1813 "HOVON 156 AML" @default.
- Q66060286 P2899 "+18" @default.
- Q66060286 P3098 "NCT04027309" @default.
- Q66060286 P31 Q30612 @default.
- Q66060286 P580 "2019-09-01T00:00:00Z" @default.
- Q66060286 P582 "2023-05-01T00:00:00Z" @default.
- Q66060286 P6099 Q42824827 @default.
- Q66060286 P6153 Q633529 @default.
- Q66060286 P8363 Q78089383 @default.